Share Price and Basic Stock Data
Last Updated: November 20, 2025, 12:10 am
| PEG Ratio | 1.72 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Everest Organics Ltd operates within the pharmaceuticals sector, focusing on the production of active pharmaceutical ingredients (APIs). The company reported a market capitalization of ₹394 Cr and a share price of ₹406. In terms of sales performance, the company recorded a total revenue of ₹183 Cr for the fiscal year ending March 2023, which represents a decline from ₹200 Cr in the previous year. However, the trailing twelve months (TTM) sales stood at ₹181 Cr, indicating a slight recovery trend. Quarterly sales figures show fluctuations, with the highest quarterly sales of ₹52.62 Cr recorded in March 2024, followed by a drop to ₹32.45 Cr in June 2024. The overall sales trajectory suggests volatility, influenced by market conditions and operational challenges. The company has a reported operating profit margin (OPM) of 8.25%, which is relatively low compared to typical sector norms, indicating room for improvement in cost management and operational efficiency.
Profitability and Efficiency Metrics
Profitability metrics for Everest Organics reveal a challenging landscape. The company reported a net profit of ₹6 Cr for the year ending March 2023, translating to a net profit margin of merely 3.28%. This is significantly lower than the average margins seen in the pharmaceuticals industry, which typically range between 10% and 20%. The return on equity (ROE) stood at 2.23%, while the return on capital employed (ROCE) was recorded at 1.76%, both of which are below industry benchmarks. Operating profit for the fiscal year was notably weak, with a reported operating profit of ₹1 Cr. The company’s interest coverage ratio (ICR) of 1.52x indicates a precarious position in meeting interest obligations, reflecting potential liquidity issues. The cash conversion cycle (CCC) was reported at 17 days, suggesting a relatively efficient management of working capital, but this is overshadowed by the overall profitability concerns.
Balance Sheet Strength and Financial Ratios
Examining Everest Organics’ balance sheet reveals a mixed picture of financial health. The company’s total borrowings stood at ₹48 Cr against reserves of ₹60 Cr, indicating a manageable debt level. However, the debt-to-equity ratio of 0.68x suggests reliance on debt financing, which can pose risks in adverse market conditions. The current ratio of 1.06x is marginally above the ideal benchmark of 1.0, indicating adequate short-term liquidity. The price-to-book value (P/BV) ratio of 3.50x reflects a premium valuation compared to its book value of ₹72.03 per share, which may indicate market optimism or overvaluation. Additionally, the company’s total assets were recorded at ₹224 Cr, with fixed assets amounting to ₹50 Cr, pointing towards a stable asset base. However, the declining trend in net profit over the past few years raises concerns regarding long-term sustainability and operational effectiveness.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Everest Organics showcases a significant concentration of ownership among promoters, who hold 60.99% of the company’s shares as of June 2025. This level of promoter ownership can instill confidence among investors, as it often aligns management’s interests with those of shareholders. Conversely, foreign institutional investors (FIIs) are not reported to hold any shares, and domestic institutional investors (DIIs) possess a minimal 0.02% stake. This lack of institutional backing may raise concerns regarding the stock’s liquidity and overall market perception. The number of shareholders has decreased from 11,250 in September 2022 to 8,281 in June 2025, indicating potential disengagement from retail investors. The public shareholding rose to 38.99%, reflecting some interest but still highlighting a need for broader market participation to enhance investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, Everest Organics faces several challenges and opportunities. The primary risks include volatile sales performance, low profitability margins, and a high reliance on debt, which could hinder growth prospects. The company must focus on improving operational efficiency and profitability to align with industry standards. Opportunities lie in leveraging its existing assets and improving product offerings to capture a larger market share within the pharmaceuticals sector. Additionally, strategic partnerships or expansions could aid in mitigating risks associated with market fluctuations. Strengthening investor relations and enhancing shareholder value will be crucial for regaining market confidence. Overall, while Everest Organics has the potential for recovery, it must navigate its current challenges effectively to ensure sustainable growth and profitability in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Everest Organics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 159 Cr. | 127 | 247/84.3 | 35.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,768 Cr. | 438 | 479/192 | 98.7 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.0 Cr. | 43.1 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.7 Cr. | 26.4 | 29.1/17.0 | 92.1 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,252.29 Cr | 1,184.24 | 53.13 | 202.47 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43.03 | 45.97 | 43.29 | 50.75 | 42.67 | 49.45 | 52.51 | 52.62 | 32.45 | 44.05 | 42.05 | 40.93 | 53.81 |
| Expenses | 44.67 | 43.20 | 45.79 | 48.47 | 40.15 | 46.74 | 49.71 | 49.67 | 36.11 | 40.62 | 38.03 | 37.49 | 49.37 |
| Operating Profit | -1.64 | 2.77 | -2.50 | 2.28 | 2.52 | 2.71 | 2.80 | 2.95 | -3.66 | 3.43 | 4.02 | 3.44 | 4.44 |
| OPM % | -3.81% | 6.03% | -5.78% | 4.49% | 5.91% | 5.48% | 5.33% | 5.61% | -11.28% | 7.79% | 9.56% | 8.40% | 8.25% |
| Other Income | 0.39 | 0.22 | 5.65 | 0.69 | 0.22 | 0.24 | 0.13 | 0.30 | 0.33 | 0.14 | 0.00 | 0.22 | 0.55 |
| Interest | 0.69 | 0.85 | 0.81 | 0.95 | 1.29 | 1.49 | 1.45 | 1.24 | 1.29 | 1.35 | 1.40 | 1.15 | 1.31 |
| Depreciation | 0.99 | 1.13 | 1.10 | 1.26 | 1.29 | 1.32 | 1.33 | 1.85 | 1.47 | 1.47 | 1.47 | 1.56 | 1.52 |
| Profit before tax | -2.93 | 1.01 | 1.24 | 0.76 | 0.16 | 0.14 | 0.15 | 0.16 | -6.09 | 0.75 | 1.15 | 0.95 | 2.16 |
| Tax % | -5.80% | 6.93% | -21.77% | 85.53% | 75.00% | 78.57% | 93.33% | 62.50% | 0.00% | 0.00% | 0.87% | -206.32% | 35.19% |
| Net Profit | -2.75 | 0.94 | 1.52 | 0.11 | 0.04 | 0.03 | 0.02 | 0.06 | -6.09 | 0.75 | 1.14 | 2.91 | 1.41 |
| EPS in Rs | -3.44 | 1.18 | 1.90 | 0.14 | 0.05 | 0.04 | 0.02 | 0.08 | -7.61 | 0.94 | 1.42 | 3.00 | 1.45 |
Last Updated: August 19, 2025, 3:46 pm
Below is a detailed analysis of the quarterly data for Everest Organics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 53.81 Cr.. The value appears strong and on an upward trend. It has increased from 40.93 Cr. (Mar 2025) to 53.81 Cr., marking an increase of 12.88 Cr..
- For Expenses, as of Jun 2025, the value is 49.37 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 37.49 Cr. (Mar 2025) to 49.37 Cr., marking an increase of 11.88 Cr..
- For Operating Profit, as of Jun 2025, the value is 4.44 Cr.. The value appears strong and on an upward trend. It has increased from 3.44 Cr. (Mar 2025) to 4.44 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Jun 2025, the value is 8.25%. The value appears to be declining and may need further review. It has decreased from 8.40% (Mar 2025) to 8.25%, marking a decrease of 0.15%.
- For Other Income, as of Jun 2025, the value is 0.55 Cr.. The value appears strong and on an upward trend. It has increased from 0.22 Cr. (Mar 2025) to 0.55 Cr., marking an increase of 0.33 Cr..
- For Interest, as of Jun 2025, the value is 1.31 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.15 Cr. (Mar 2025) to 1.31 Cr., marking an increase of 0.16 Cr..
- For Depreciation, as of Jun 2025, the value is 1.52 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.56 Cr. (Mar 2025) to 1.52 Cr., marking a decrease of 0.04 Cr..
- For Profit before tax, as of Jun 2025, the value is 2.16 Cr.. The value appears strong and on an upward trend. It has increased from 0.95 Cr. (Mar 2025) to 2.16 Cr., marking an increase of 1.21 Cr..
- For Tax %, as of Jun 2025, the value is 35.19%. The value appears to be increasing, which may not be favorable. It has increased from -206.32% (Mar 2025) to 35.19%, marking an increase of 241.51%.
- For Net Profit, as of Jun 2025, the value is 1.41 Cr.. The value appears to be declining and may need further review. It has decreased from 2.91 Cr. (Mar 2025) to 1.41 Cr., marking a decrease of 1.50 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.45. The value appears to be declining and may need further review. It has decreased from 3.00 (Mar 2025) to 1.45, marking a decrease of 1.55.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:23 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 96 | 106 | 99 | 107 | 112 | 156 | 167 | 182 | 200 | 183 | 197 | 159 | 188 |
| Expenses | 91 | 98 | 94 | 101 | 105 | 138 | 148 | 159 | 194 | 182 | 186 | 152 | 171 |
| Operating Profit | 5 | 8 | 6 | 6 | 7 | 18 | 19 | 23 | 6 | 1 | 11 | 7 | 17 |
| OPM % | 6% | 7% | 6% | 6% | 6% | 11% | 12% | 13% | 3% | 1% | 6% | 5% | 9% |
| Other Income | 1 | -0 | -0 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 1 | 1 | 1 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 | 5 | 5 |
| Depreciation | 2 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 6 | 6 | 6 |
| Profit before tax | 1 | 2 | 0 | 2 | 2 | 12 | 14 | 17 | 2 | 0 | 1 | -3 | 7 |
| Tax % | 21% | 20% | 18% | 24% | 28% | 39% | 23% | 21% | 34% | 311% | 77% | -60% | |
| Net Profit | 1 | 2 | 0 | 1 | 2 | 8 | 11 | 14 | 1 | -0 | 0 | -1 | 7 |
| EPS in Rs | 0.54 | 1.69 | 2.14 | 9.39 | 13.62 | 17.15 | 1.42 | -0.22 | 0.18 | -1.33 | 7.06 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 11% | 7% | 9% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | -100.00% | 100.00% | 300.00% | 37.50% | 27.27% | -92.86% | -100.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -200.00% | 200.00% | 200.00% | -262.50% | -10.23% | -120.13% | -7.14% |
Everest Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2014-2015 to 2022-2023.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -1% |
| 3 Years: | -7% |
| TTM: | -3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 204% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 44% |
| 1 Year: | 182% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 6% |
| 3 Years: | -1% |
| Last Year: | -2% |
Last Updated: September 5, 2025, 3:26 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106 | 100 | 117 | 105 | 124 | 95 | 97 | 102 | 125 | 152 | 185 | 202 |
| Inventory Days | 46 | 44 | 55 | 73 | 72 | 71 | 102 | 110 | 110 | 139 | 128 | 166 |
| Days Payable | 184 | 184 | 235 | 260 | 251 | 190 | 211 | 183 | 212 | 282 | 324 | 351 |
| Cash Conversion Cycle | -32 | -40 | -63 | -83 | -55 | -24 | -12 | 29 | 24 | 9 | -11 | 17 |
| Working Capital Days | -43 | -30 | -38 | -50 | -34 | -15 | 7 | 21 | 9 | -12 | -21 | 3 |
| ROCE % | 13% | 19% | 11% | 13% | 13% | 35% | 35% | 34% | 6% | 4% | 6% | 2% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.97 | 0.17 | -0.23 | 1.43 | 17.14 |
| Diluted EPS (Rs.) | -2.97 | 0.17 | -0.23 | 1.43 | 17.14 |
| Cash EPS (Rs.) | 4.81 | 7.42 | 5.36 | 6.17 | 21.36 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 72.03 | 57.30 | 57.77 | 58.50 | 58.22 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 72.03 | 57.30 | 57.77 | 58.50 | 58.22 |
| Dividend / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.50 | 1.50 |
| Revenue From Operations / Share (Rs.) | 164.23 | 246.55 | 228.81 | 250.06 | 226.96 |
| PBDIT / Share (Rs.) | 8.14 | 14.84 | 9.84 | 10.80 | 29.88 |
| PBIT / Share (Rs.) | 2.00 | 7.60 | 4.25 | 6.05 | 25.66 |
| PBT / Share (Rs.) | -3.34 | 0.76 | 0.11 | 2.17 | 21.59 |
| Net Profit / Share (Rs.) | -1.33 | 0.17 | -0.22 | 1.43 | 17.14 |
| PBDIT Margin (%) | 4.95 | 6.01 | 4.30 | 4.31 | 13.16 |
| PBIT Margin (%) | 1.22 | 3.08 | 1.85 | 2.42 | 11.30 |
| PBT Margin (%) | -2.03 | 0.30 | 0.04 | 0.86 | 9.51 |
| Net Profit Margin (%) | -0.80 | 0.07 | -0.09 | 0.57 | 7.55 |
| Return on Networth / Equity (%) | -1.84 | 0.30 | -0.39 | 2.44 | 29.44 |
| Return on Capital Employeed (%) | 2.30 | 9.12 | 5.28 | 7.39 | 35.38 |
| Return On Assets (%) | -0.57 | 0.06 | -0.09 | 0.64 | 10.13 |
| Long Term Debt / Equity (X) | 0.13 | 0.31 | 0.25 | 0.23 | 0.12 |
| Total Debt / Equity (X) | 0.68 | 1.26 | 1.10 | 0.82 | 0.42 |
| Asset Turnover Ratio (%) | 0.70 | 0.92 | 0.96 | 1.28 | 1.42 |
| Current Ratio (X) | 1.06 | 0.93 | 0.96 | 1.05 | 1.15 |
| Quick Ratio (X) | 0.73 | 0.66 | 0.62 | 0.67 | 0.72 |
| Inventory Turnover Ratio (X) | 2.19 | 2.73 | 2.83 | 3.77 | 3.85 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | -219.53 | 69.94 | 8.74 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 9.32 | 16.19 | 7.02 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 319.53 | 30.06 | 91.26 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 90.68 | 83.81 | 92.98 |
| Interest Coverage Ratio (X) | 1.52 | 2.17 | 2.38 | 2.78 | 7.34 |
| Interest Coverage Ratio (Post Tax) (X) | 0.75 | 1.03 | 0.94 | 1.37 | 5.21 |
| Enterprise Value (Cr.) | 285.94 | 148.80 | 126.35 | 177.17 | 202.22 |
| EV / Net Operating Revenue (X) | 1.79 | 0.75 | 0.69 | 0.88 | 1.11 |
| EV / EBITDA (X) | 36.15 | 12.53 | 16.05 | 20.51 | 8.46 |
| MarketCap / Net Operating Revenue (X) | 1.53 | 0.46 | 0.41 | 0.69 | 1.01 |
| Retention Ratios (%) | 0.00 | 0.00 | 319.53 | 30.05 | 91.25 |
| Price / BV (X) | 3.50 | 2.00 | 1.65 | 2.97 | 3.95 |
| Price / Net Operating Revenue (X) | 1.53 | 0.46 | 0.41 | 0.69 | 1.01 |
| EarningsYield | -0.01 | 0.00 | 0.00 | 0.01 | 0.07 |
After reviewing the key financial ratios for Everest Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.97. This value is below the healthy minimum of 5. It has decreased from 0.17 (Mar 24) to -2.97, marking a decrease of 3.14.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.97. This value is below the healthy minimum of 5. It has decreased from 0.17 (Mar 24) to -2.97, marking a decrease of 3.14.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.81. This value is within the healthy range. It has decreased from 7.42 (Mar 24) to 4.81, marking a decrease of 2.61.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.03. It has increased from 57.30 (Mar 24) to 72.03, marking an increase of 14.73.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.03. It has increased from 57.30 (Mar 24) to 72.03, marking an increase of 14.73.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 164.23. It has decreased from 246.55 (Mar 24) to 164.23, marking a decrease of 82.32.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 8.14. This value is within the healthy range. It has decreased from 14.84 (Mar 24) to 8.14, marking a decrease of 6.70.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 7.60 (Mar 24) to 2.00, marking a decrease of 5.60.
- For PBT / Share (Rs.), as of Mar 25, the value is -3.34. This value is below the healthy minimum of 0. It has decreased from 0.76 (Mar 24) to -3.34, marking a decrease of 4.10.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -1.33. This value is below the healthy minimum of 2. It has decreased from 0.17 (Mar 24) to -1.33, marking a decrease of 1.50.
- For PBDIT Margin (%), as of Mar 25, the value is 4.95. This value is below the healthy minimum of 10. It has decreased from 6.01 (Mar 24) to 4.95, marking a decrease of 1.06.
- For PBIT Margin (%), as of Mar 25, the value is 1.22. This value is below the healthy minimum of 10. It has decreased from 3.08 (Mar 24) to 1.22, marking a decrease of 1.86.
- For PBT Margin (%), as of Mar 25, the value is -2.03. This value is below the healthy minimum of 10. It has decreased from 0.30 (Mar 24) to -2.03, marking a decrease of 2.33.
- For Net Profit Margin (%), as of Mar 25, the value is -0.80. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to -0.80, marking a decrease of 0.87.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.84. This value is below the healthy minimum of 15. It has decreased from 0.30 (Mar 24) to -1.84, marking a decrease of 2.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.30. This value is below the healthy minimum of 10. It has decreased from 9.12 (Mar 24) to 2.30, marking a decrease of 6.82.
- For Return On Assets (%), as of Mar 25, the value is -0.57. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to -0.57, marking a decrease of 0.63.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has decreased from 0.31 (Mar 24) to 0.13, marking a decrease of 0.18.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.68. This value is within the healthy range. It has decreased from 1.26 (Mar 24) to 0.68, marking a decrease of 0.58.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.70. It has decreased from 0.92 (Mar 24) to 0.70, marking a decrease of 0.22.
- For Current Ratio (X), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 1.5. It has increased from 0.93 (Mar 24) to 1.06, marking an increase of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.73, marking an increase of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 4. It has decreased from 2.73 (Mar 24) to 2.19, marking a decrease of 0.54.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 3. It has decreased from 2.17 (Mar 24) to 1.52, marking a decrease of 0.65.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 3. It has decreased from 1.03 (Mar 24) to 0.75, marking a decrease of 0.28.
- For Enterprise Value (Cr.), as of Mar 25, the value is 285.94. It has increased from 148.80 (Mar 24) to 285.94, marking an increase of 137.14.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.79. This value is within the healthy range. It has increased from 0.75 (Mar 24) to 1.79, marking an increase of 1.04.
- For EV / EBITDA (X), as of Mar 25, the value is 36.15. This value exceeds the healthy maximum of 15. It has increased from 12.53 (Mar 24) to 36.15, marking an increase of 23.62.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 0.46 (Mar 24) to 1.53, marking an increase of 1.07.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 3. It has increased from 2.00 (Mar 24) to 3.50, marking an increase of 1.50.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 0.46 (Mar 24) to 1.53, marking an increase of 1.07.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.00 (Mar 24) to -0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Everest Organics Ltd:
- Net Profit Margin: -0.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.3% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1.84% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.75
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 64.9 (Industry average Stock P/E: 43.71)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.68
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -0.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Aroor Village, Sadasivpet Mandal, Sangareddy Dist. Telangana 502291 | e.cs@everestorganicsltd.com http://www.everestorganicsltd.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Prasad Venkata Satya Sundara Srikakolapu | Chairman & Ind.Director |
| Dr. Sri Kakarlapudi Sirisha | Managing Director |
| Mr. Srikakarlapudi Harikrishna | Whole Time Director |
| Mr. Kirankumar Rampally | Non Exe.Non Ind.Director |
| Mr. Venkata Satyanarayana Murthy Vadali | Independent Director |

